# Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

> **NCT00183937** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** PS 341
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00183937
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04-30
- **Primary completion:** 2010-10-23
- **Final completion:** 2012-06-11
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor stopped study early.
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00183937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00183937, "Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00183937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*